The US Food and Drug Administration on Wednesday authorised Pfizer's Paxlovid pill, the first anti-Covid-19 treatment pill to be authorised in the country. It will be used to treat high-risk patients with moderate to severe disease within five days of symptom onset. Pfizer said it was ready to commence delivery of the pill immediately.
The latest news comes on the back of seperate positive pandemic developments. Namely, a recent study released by Scottish scientists showed Omicron infection to be associated with about a two-thirds reduced risk of hospitalisation, a conclusion in fitting with similar studies conducted in South Africa.
Market Reaction
Markets have switched from trading in a quite a subdued fashion earlier in the session to more of a risk on mode in recent trade, with stocks, crude oil and risk sensitive currencies all gaining in recent trade. The aforementioned positive pandemic newsflow is likely contributing to a sense of optimism that while Omicron is a threat to the global economy, it does not look set to deliver a lasting blow to growth, given its lesser severity, high vaccination rates in developed countries and the upcoming rollout of effective treatments.
Note: All information on this page is subject to change. The use of this website constitutes acceptance of our user agreement. Please read our privacy policy and legal disclaimer. Opinions expressed at FXstreet.com are those of the individual authors and do not necessarily represent the opinion of FXstreet.com or its management. Risk Disclosure: Trading foreign exchange on margin carries a high level of risk, and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading, and seek advice from an independent financial advisor if you have any doubts.
Recommended content
Editors’ Picks
AUD/USD slips below 0.6700 as downbeat Australia inflation recall Aussie bears
AUD/USD drops 20 pips to 0.6690 as Aussie inflation disappoints during early Wednesday. In doing so, the risk barometer pair snaps two-day winning streak. That said, Australia’s Monthly Consumer Price Index dropped to 6.8% YoY in February versus 7.2% expected and 7.4% prior.
USD/JPY: 200-HMA prods bulls around mid-131.00s
USD/JPY struggles around intraday high as the key moving average challenges the Yen pair buyers during early Wednesday. Also testing the upside momentum are the overbought conditions of the Relative Strength Index (RSI) line, placed at 14.
Gold is in pressure mode as markets reassess banking crisis, inflation woes
Gold stays defensive around $1,972, after snapping a two-day losing streak the previous day, as bulls seek more clues amid a cautious mood ahead of the top-tier data. Also challenging the XAU/USD price could be the mixed concerns about the market’s recent optimism that the banking turmoil is over.
This is how Arbitrum and Optimism are dragging users away from Ethereum
Arbitrum became the highlight of the month as the Layer-2 (L2) blockchain launched its native token, ARB. Since then, the L2 narrative that was once the talking point of 2022 has exploded again.
Unfazed: Confidence edges higher despite banking situation
Consumers may not love the present conditions, but a slightly more upbeat take on where things are headed was enough to give overall confidence a nudge in the right direction in March.